Omada Health just posted its most profitable quarter as a public company, and the equity debate is no longer whether virtual chronic care can print GAAP profit. The question is whether that profit is a scalable franchise or a Cigna-channel print dressed as a platform. Second-quarter revenue rose 43% as members crossed one million. Gross margin reached a company record. That combination is the first clean evidence that AI-assisted Care Team staffing can convert enrollment into earnings, not just into a larger loss.
Concentration is the tension the print does not resolve. Two affiliates of The Cigna Group still dominate the book and the receivable line, and Cigna Ventures remains a five-percent-plus holder. Management broadened Health Care Service Corporation coverage by an additional 1.5 million lives and closed a first GLP-1 prescribing customer. Those are real diversification steps. They are not yet large enough to change the economic identity of the company. Trailing twelve-month revenue per member only edged up to $284, so growth is still mostly volume.
Cash of $222 million and no debt give the company time. First-half operations still used cash even as the income statement turned positive, so the quality of the profit remains an open test. Investor Day then put an 80% non-GAAP gross-margin destination on the board. A separate 30% adjusted-EBITDA destination sat beside it. The market, near $20 per share and about $1.3 billion of equity value, is paying a software multiple for a still-concentrated care vendor. Does enrollment, mix, and cash conversion support that destination, or does partner risk re-rate the story first?